How Is Dent Disease Managed to Preserve Kidney and Bone Health?

Dent disease is caused by mutations in the CLCN5 gene, known as Dent-1, or the OCRL gene, known as Dent-2. These genes affect how the kidney’s proximal tubule reabsorbs filtered proteins and minerals. As a result, patients develop low-molecular-weight proteinuria, meaning small proteins spill into the urine, along with excessive urinary calcium loss called hypercalciuria. Over time this leads to kidney stones, nephrocalcinosis which is calcium deposition within kidney tissue, and progressive loss of kidney function. Affected males typically present in early childhood.

Initial evaluation should establish the extent of kidney involvement and future risk. This includes measuring glomerular filtration rate, urine protein excretion, and urinary calcium and citrate. Kidney imaging with ultrasound or low-dose CT helps identify stones or nephrocalcinosis. Bone and mineral parameters are essential since phosphate wasting and vitamin D abnormalities can impair skeletal development.

These labs include serum calcium, phosphorus, alkaline phosphatase, vitamin D, and parathyroid hormone. In children, growth tracking is critical. In Dent-2 disease, screening for intellectual disability and cataracts is also recommended.

Treatment is supportive rather than curative. Thiazide diuretics are commonly used to lower urinary calcium excretion, often by more than 40 percent at adequate doses. These drugs increase calcium reabsorption in the distal tubule, but they carry risks including low potassium, dehydration, and muscle cramping. Close monitoring is required.

Drugs that block the renin-angiotensin system, such as ACE inhibitors or ARBs, do not meaningfully reduce the characteristic proteinuria and have uncertain benefit for slowing kidney decline in Dent disease.

Bone disease often responds to targeted therapy. Vitamin D supplementation and phosphate repletion can improve bone mineralization and, in some cases, reduce hypercalciuria. Growth hormone therapy has been used in children with growth failure without accelerating kidney function loss.

Long-term surveillance is essential. At minimum, patients should have yearly monitoring of kidney function, urinary calcium, blood pressure, hemoglobin, and serum calcium and phosphorus. As chronic kidney disease advances, monitoring should become more frequent.

Avoidance of nephrotoxins is critical, including NSAIDs, aminoglycoside antibiotics, and intravenous contrast when possible.

Despite optimal care, many patients progress to end-stage kidney disease. Renal replacement therapy, including dialysis or transplantation, becomes necessary in approximately 30 to 80 percent of affected males, often between the third and fifth decades of life. Importantly, Dent disease does not recur after kidney transplantation because the defect is intrinsic to the native kidneys.

Genetic testing plays a key role in diagnosis and family counseling. At-risk male relatives should be evaluated through molecular testing or by measuring urinary low-molecular-weight proteins, which can identify affected individuals before significant kidney damage occurs.